Compare Estee Lauder Companies Inc (EL) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Medtronic PLC — how do they compare? Estee Lauder Companies Inc trades at $87.79 (market cap $31.54B), while Medtronic PLC trades at $90.58 (market cap $114.45B). The key difference: Medtronic PLC is far larger — about 3.6× Estee Lauder Companies Inc's market cap, and Medtronic PLC pays the higher dividend (3.22%). Which is the better fit depends on your goals.
| EL | MDT | |
|---|---|---|
Market Cap | $31.54B | $114.45B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $105.35 |
52-Week Low | $67.23 | $73.75 |
Enterprise Value | $37.72B | $133.19B |
Dividend Yield | 1.61% | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $88.35, up 3.35% with a bullish technical signal and recent earnings beats. The stock shows strong institutional interest with Bank of America increasing its stake by 950.9% in Q1 2026. Despite negative net income margins, the company maintains a robust gross margin of 74.71% and has upcoming Q2 2026 earnings expected at $0.3197 per share. Recent corporate developments include a new fragrance launch and executive appointments.
The outlook remains cautiously optimistic with a consensus price target of $91.67 offering 3.8% upside potential. Key risks include declining revenue trends and negative profitability, while opportunities lie in product innovation and digital engagement. The stock faces resistance near $90-$93 levels with support at $86.
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
